title: Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor.
abstract: Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among the aging population in the many western countries. The introduction of molecular inhibitors of vascular endothelial growth factor (VEGF), such as pegaptanib, ranibizumab, and bevacizumab, as treatments for wet AMD has provided new hope for affected patients. Now we have these treatment options, which have the possibility to improve or maintain visual acuity for patients suffering from AMD. The treatment needs to be optimized and this is in progress. Based on emerging evidence, adopting a variable VEGF inhibitor-dosing strategy guided by visual acuity assessment and optical coherence tomography are now being tried to reduce the frequency of injections. VEGF inhibitors in combination with photodynamic therapy are another way to optimize treatment. Physicians are waiting for new guidelines for the management of AMD and the results of current and upcoming trials systematically addressing these issues will be expected to provide it.
authors.affiliation: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Yukio
authors.initials: Y
authors.lastname: Sassa
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Hata
references.citation: Am J Ophthalmol. 2003 Dec;136(6):1049-61
references.pmid: 14644215
references.citation: Ophthalmology. 2002 Jun;109(6):1092-7
references.pmid: 12045049
references.citation: J BUON. 2008 Jan-Mar;13(1):31-6
references.pmid: 18404783
references.citation: Am J Ophthalmol. 1980 Dec;90(6):810-6
references.pmid: 7446668
references.citation: Arch Ophthalmol. 2004 Apr;122(4):477-85
references.pmid: 15078664
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8
references.pmid: 17186262
references.citation: Adv Ther. 1997 Sep-Oct;14(5):275-80
references.pmid: 10174620
references.citation: Retina. 2006 May-Jun;26(5):495-511
references.pmid: 16770255
references.citation: Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34
references.pmid: 11033038
references.citation: Ophthalmology. 2006 Jun;113(6):992-1001.e6
references.pmid: 16647134
references.citation: N Engl J Med. 2004 Dec 30;351(27):2805-16
references.pmid: 15625332
references.citation: Am J Ophthalmol. 2008 Feb;145(2):239-248
references.pmid: 18222192
references.citation: Retina. 2002 Feb;22(1):6-18
references.pmid: 11884872
references.citation: N Engl J Med. 2006 Oct 5;355(14):1419-31
references.pmid: 17021318
references.citation: Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):899-906
references.pmid: 19308441
references.citation: Biochem Biophys Res Commun. 1998 Nov 27;252(3):743-6
references.pmid: 9837777
references.citation: Arch Ophthalmol. 1984 Nov;102(11):1640-2
references.pmid: 6208888
references.citation: Retina. 2002 Apr;22(2):143-52
references.pmid: 11927845
references.citation: Am J Ophthalmol. 2006 Jul;142(1):1-9
references.pmid: 16815245
references.citation: Invest Ophthalmol Vis Sci. 2003 May;44(5):2141-6
references.pmid: 12714654
references.citation: Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1907-10
references.pmid: 15914602
references.citation: Ophthalmology. 2006 Sep;113(9):1508.e1-25
references.pmid: 16828500
references.citation: Ophthalmology. 2009 Nov;116(11):2175-81.e1
references.pmid: 19700194
references.citation: Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33
references.pmid: 15671306
references.citation: J Clin Invest. 2000 Aug;106(4):541-50
references.pmid: 10953029
references.citation: Am J Ophthalmol. 1981 Jun;91(6):785-8
references.pmid: 7246702
references.citation: Am J Ophthalmol. 2007 Apr;143(4):566-83
references.pmid: 17386270
references.citation: Ophthalmology. 2006 Mar;113(3):363-372.e5
references.pmid: 16458968
references.citation: Ophthalmology. 2007 Sep;114(9):1702-12
references.pmid: 17509689
references.citation: Retina. 2009 Apr;29(4):523-9
references.pmid: 19262441
references.citation: Neurosignals. 2005;14(5):207-21
references.pmid: 16301836
references.citation: Ophthalmology. 1997 Jan;104(1):7-21
references.pmid: 9022098
references.citation: N Engl J Med. 2006 Oct 5;355(14):1432-44
references.pmid: 17021319
references.citation: Aust N Z J Ophthalmol. 1995 Nov;23(4):293-8
references.pmid: 11980075
references.citation: Doc Ophthalmol. 2009 Dec;119(3):163-9
references.pmid: 20101800
references.citation: Arch Ophthalmol. 1985 May;103(5):708-11
references.pmid: 2581536
references.citation: Nat Med. 2008 Feb;14(2):194-8
references.pmid: 18223656
references.citation: Arch Ophthalmol. 1992 Aug;110(8):1155-9
references.pmid: 1497531
references.citation: Circulation. 1998 Jan 6-13;97(1):99-107
references.pmid: 9443437
references.citation: Br J Ophthalmol. 2006 Nov;90(11):1344-9
references.pmid: 16854824
references.citation: Acta Ophthalmol. 2008 Jun;86(4):372-6
references.pmid: 18028234
references.citation: Clin Exp Ophthalmol. 2008 Nov;36(8):748-55
references.pmid: 19128380
references.citation: Retina. 2005 Feb-Mar;25(2):119-34
references.pmid: 15689800
references.citation: Arch Ophthalmol. 2001 Feb;119(2):198-207
references.pmid: 11176980
references.citation: Retina. 2007 Apr-May;27(4):439-44
references.pmid: 17420695